Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 58, 2023 - Issue 5
Submit an article Journal homepage
1,812
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study

Erika R. Bjørnåa HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, NorwayView further author information
,
Martine T. Engelsena HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, NorwayView further author information
,
Hashem B. El-Seragb Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USAView further author information
&
Eivind Ness-Jensena HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway;c Medical Department, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway;d Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6005-0729View further author information
ORCID Icon
Pages 505-511 | Received 09 Sep 2022, Accepted 19 Oct 2022, Published online: 31 Oct 2022

References

  • Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330–9337.
  • Husain N, Blais P, Kramer J, et al. Nonalcoholic fatty liver disease (NAFLD) in the veterans administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014;40(8):949–954.
  • Kanwal F, Kramer JR, Duan Z, et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol. 2016;14(2):301–308.e1-2.
  • Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276.
  • Wattacheril J, Chalasani N. Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology 2012;56(4):1580–1584.
  • Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51(5):1820–1832.
  • Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285.
  • Farrell GC. The liver and the waistline: Fifty years of growth. J Gastroenterol Hepatol. 2009;24 Suppl 3:S105–S118.
  • Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801.
  • Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
  • Pimpin L, Cortez-Pinto H, Negro F, EASL HEPAHEALTH Steering Committee, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718–735.
  • Zhu J-Z, Dai Y-N, Wang Y-M, et al. Prevalence of nonalcoholic fatty liver disease and economy. Dig Dis Sci. 2015;60(11):3194–3202.
  • Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
  • Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–S64.
  • Krokstad S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT study, Norway. Int J Epidemiol. 2013;42(4):968–977.
  • Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.
  • Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124(1):71–79.
  • Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101(1):76–82.
  • Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388–1393.
  • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–357.
  • Kim WR, Flamm SL, Di Bisceglie AM, Public Policy Committee of the American Association for the Study of Liver Disease, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363–1370.
  • Engelmann G. Biomarkers in focus: Alanine aminotransferase. In: Patel VB, Preedy VR, editors. Biomarkers in liver disease. Dordrecht: Springer Netherlands; 2017. p. 267–280.
  • Isabela Andronescu C, Roxana Purcarea M, Aurel Babes P. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease. J Med Life. 2018;11(3):243–246.
  • Mørch Stene LC, Gulseth , Hanne L. Diabetes i Norge FHI; [updated 2017 June 2; cited 2020 June 22]. Available from: https://www.fhi.no/nettpub/hin/ikke-smittsomme/diabetes/.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.